BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 22663169)

  • 1. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
    Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
    J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-cause and disease-related health care costs associated with recurrent venous thromboembolism.
    Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Hossou Y; Schein J; Kaatz S
    Thromb Haemost; 2013 Dec; 110(6):1288-97. PubMed ID: 24085327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations.
    Spyropoulos AC; Lin J
    J Manag Care Pharm; 2007; 13(6):475-86. PubMed ID: 17672809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Manag Care Spec Pharm; 2015 Oct; 21(10):965-72. PubMed ID: 26402395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.
    MacDougall DA; Feliu AL; Boccuzzi SJ; Lin J
    Am J Health Syst Pharm; 2006 Oct; 63(20 Suppl 6):S5-15. PubMed ID: 17032933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
    Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
    J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
    [No Abstract]   [Full Text] [Related]  

  • 11. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
    McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
    J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis.
    Lang K; Patel AA; Munsell M; Bookhart BK; Mody SH; Schein JR; Menzin J
    J Thromb Thrombolysis; 2015 May; 39(4):434-42. PubMed ID: 25079971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery.
    Baser O; Supina D; Sengupta N; Wang L; Kwong L
    Am J Health Syst Pharm; 2010 Sep; 67(17):1438-45. PubMed ID: 20720243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
    Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
    J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
    Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
    J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet agents for the treatment of deep venous thrombosis.
    Flumignan CD; Nakano LC; Baptista-Silva JC; Flumignan RL
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD012369. PubMed ID: 35876829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Incidence and Economic Burden of In-Hospital Venous Thromboembolism in the United States.
    Shahi A; Chen AF; Tan TL; Maltenfort MG; Kucukdurmaz F; Parvizi J
    J Arthroplasty; 2017 Apr; 32(4):1063-1066. PubMed ID: 27866951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective.
    Casciano JP; Dotiwala Z; Kemp R; Li C; Cai J; Preblick R
    Am J Health Syst Pharm; 2015 Feb; 72(4):291-300. PubMed ID: 25631836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.
    Mahan CE; Borrego ME; Woersching AL; Federici R; Downey R; Tiongson J; Bieniarz MC; Cavanaugh BJ; Spyropoulos AC
    Thromb Haemost; 2012 Aug; 108(2):291-302. PubMed ID: 22739656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.
    LaMori JC; Shoheiber O; Mody SH; Bookhart BK
    Clin Ther; 2015 Jan; 37(1):62-70. PubMed ID: 25524389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.